Evaluación de tecnología sanitaria: informe de respuesta rápida. Tocilizumab para el tratamiento de la artritis idiopática juvenil poliarticular

  • Pablo García Munitis Hospital El Cruce, Florencio Varela, Buenos Aires, Argentina
Palabras clave: artritis idiopática juvenil, tocilizumab, interleukina-6

Resumen

El grupo de las AIJ son afecciones raras con consecuencias sobre la calidad de vida de los pacientes afectados y los costos para los pacientes y los sistemas de salud. El abordaje actual incluye la utilización de corticoides intraarticulares, metotrexato semanal y agentes biológicos. Objetivo: Evaluar la evidencia disponible acerca de la eficacia y seguridad para el uso de tocilizumab en pacientes con Artritis Idiopática Juvenil poliarticular.

Biografía del autor/a

Pablo García Munitis, Hospital El Cruce, Florencio Varela, Buenos Aires, Argentina
Reumatología Pediátrica

Citas

I. Ross P, Cassidy J. Chronic arthritis in Childhood. Cassidy J.Ross P sixth ed. Philadelphia:Saunders/Elsevier; 2010:211-235.

II. Espada DG. Artritis idiopática juvenil. Parte 1: Diagnóstico, patogenia y manifestaciones clínicas. Arch Argent Pediatr 2009; 107(5):441-448.

III. de Inocencio Arocena J, Casado Picón R. Artritis idiopática juvenil. Introducción. Criterios de clasificación, mejoría, recaída y remisión. Epidemiología y periodicidad de las revisiones oftalmológicas. Protoc Diagn Ter Pediatr. 2014; 1:1-8.

IV. de Inocencio Arocena J, Casado Picón R. Artritis idiopática juvenil poliarticular. Protoc Diagn Ter Pediatr. 2014; 1:21-6.

V. Rosenberg A, Oen K. Polyarthritis. Cassidy J. Ross P sixth ed. hiladelphia: Saunders/Elsevier; 2010:249-261.

VI. Cuttica R et al. Guias de práctica clínica en Artritis Idiopática Juvenil 2011.

VII. de Inocencio Arocena J. Terapia biológica en la artritis idiopática juvenil An Pediatr Contin. 2012; 10(6):343-7.

VIII. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000 Mar 16; 342(11):763-9.

IX. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003 Jan; 48 (1):218-26.

X. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007 Sep; 56(9):3096-106.

XI. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008 Aug 21; 359(8):810-20.

XII. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008 Aug 2; 372(9636):383-91.

XIII. Brunner HI. Tocilizumab for treating juvenile idiopathic arthritis. Expert OpinBiolTher. 2016; 16(4):559-66. doi: 10.1517/14712598.2016.1150997. Epub 2016 Feb 27.

XIV. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015; 74:1110–17.

XV. http://www.anmat.gov.ar/Medicamentos/basedat.asp (fecha 29/06/17)

XVI. Moroldo MB, Ruperto N, Espada G, Russo R, Liberatore D, Cuttica R, Giacomone D, Garay S, De Inocencio J, De Cunto C for the Paediatric Rheumatology International Trials Organisation (PRINTO):The Argentinian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ).ClinExpRheumatol. 2001; 19 (Suppl. 23): S10-14.

XVII. Ruperto N, Martini A, Landgraf JM, Singh G: How to obtain further information about the CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE (CHAQ) and the Child Health Questionnaire (CHQ). ClinExpRheumatol. 2001; 19 (Suppl. 23): ii.

XVIII. Ruperto N, Martini A for the Paediatric Rheumatology International Trials Organisation (PRINTO).Quality of life in juvenile idiopathic arthritis patients compared to healthy children. ClinExpRheumatol. 2001; 19 (suppl. 23):S1-S172.

XIX. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Preliminary definition of IMPROVEMENT in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-1209.

XX. Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess 2016; 20(34).

XXI. A marilyo G, Tarp S, Foeldvari I, Cohen N, Woo JM, Christensen R, Furst DE. Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials. Semin Arthritis Rheum. 2016 Dec; 46(3):312-318.

XXII. Tocilizumab (Actemra - Hoffmann-La Roche Limited) new indication: polyarticular juvenile idiopathic arthritis. Health Technology Assessment (HTA) Database.2014. http://www.cadth.ca/media/cdr/complete/cdr_ complete_ Actemra_ Mar_ 24_ 14_ e.pdf

XXIII. Tocilizumab (RoActemra®) Health Technology Assessment (HTA) Database.2014

XXIV. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Pérez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman, E, Spindler A, Baildam E, Gámir M.L, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatol. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.Ann Rheum Dis 2015 74: 1110-1117 originally published online May 16, 2014.

XXV. Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, Nerome Y, Iwata N, Murata T, Miyoshi M, Nishimoto N, Kishimoto T. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012 Feb; 22(1):109-15.

XXVI. National Institute for Health and Care Excellence (NICE). Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis. London (UK): National Institute for Health and Care Excellence (NICE); 2015 Dec 16. 57 p. (Technology appraisal guidance; no. 373).

XXVII. ht t ps://ser v icios.pami.org.ar/vademecum /v iews/ consultaPublica/listado.zul

XXVIII. A ctemra (tocilizumab) injection, for intravenous use [Prescribing information]. South San Francisco (CA): Genentech; 2014. Available from: http://www.gene.com/ download/pdf/actemra_pre scribing.pdf

XXIX. www.anthem.com/medicalpolicies/policies/mp_pw_ c122789.htm

XXX. www.cadth.ca/sites/default/files/cdr/complete/cdr_ complete_Actemra_Mar_24_14_e.pdf

XXXI. http://www.ioma.gba.gov.ar/archivos/coberturas.html

XXXII. http://www.osplad.org.ar/

XXXIII. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011; 13:R141.

XXXIV. Ruperto N, Giannini E, Pistorio A, Brunner H, Martini A, Lovell D. Is It Time to Move to Active Comparator Trials in Juvenile Idiopathic Arthritis? A Review of Current Study Designs. Arthritis & Rheumatism 2010; 62, 11:3131–3139.

Publicado
2018-06-01
Cómo citar
1.
García Munitis P. Evaluación de tecnología sanitaria: informe de respuesta rápida. Tocilizumab para el tratamiento de la artritis idiopática juvenil poliarticular. Rev. Argent. Reumatol. [Internet]. 1 de junio de 2018 [citado 6 de febrero de 2023];29(2):10 -15. Disponible en: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/526
Sección
Artículo Original